It will describe how the company’s drug candidate SAR-20351 “significantly reduces” tumour growth in disease models for pancreatic, colon, skin and kidney cancers, plus B-cell lymphoma.
Positive results were gleaned when the prospective treatment was used on its own and in combination with chemotherapy.
The early-stage study suggests SAR-20351 promotes an anti-tumour effect by activating the local immune system to attack cancer cells.
Chief executive Tim Mitchell said: “Our data suggest that our TYK2/JAK1 inhibitors also offer the potential advantage of oral delivery; this contrasts with currently marketed cancer immunotherapies, which can only be dosed by injection.”
The poster will be presented at the American Association for Cancer Research National Cancer Institute European Organisation for Research and Treatment of Cancer International Conference in Boston on October 29.